Loading organizations...
§ Venture Capital · Cranbury, NJ, USA
Single-family office venture fund for private equity and venture capital, targeting early/seed stage unique technology.
Founded in 2022 and led by principal Michael J Hennessy Jr and chief operating officer William R Hagaman, GenHenn Capital is a Cranbury, New Jersey-based single-family office. Operating as a family office venture fund, the organization deploys its own capital into private equity and venture investments across the early and seed stages. The firm focuses on mid-term to long-term investments in innovative companies developing unique technologies to improve quality of life within the life sciences, healthcare, infrastructure, biotechnology, software, and information technology sectors. The firm's recent portfolio activity includes leading a $10 million oversubscribed Series A funding round for Xenocor in April 2023 and participating in an $8.27 million Series A for Diligent Pharma. Additionally, the organization contributed to an $11 million investment round for PreciseDx in June 2025, further expanding its diverse portfolio.
GenHenn Capital has 4 tracked investments across 3 companies. The latest tracked deal is $16.0M Series B in DermaSensor in October 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 4, 2025 | DermaSensor | $16.0M Series B | — | Kern Venture Group, Preetha RAM |
| Jun 18, 2025 | PreciseDx | $11.0M Other Equity | Eventide Asset Management, Merck, Philips Ventures | Labcorp, Quest Diagnostics |
| Aug 21, 2024 | PreciseDx | $20.7M Series B | Eventide Asset Management | Labcorp, Quest Diagnostics |
| May 1, 2023 | Diligent Pharma | $8.0M Series A | Todd Johnson | Asymmetric Capital Partners, Karim Faris, Okta Ventures, Sandwith Ventures, Scale Asia Ventures, Underdog Labs, George Kurtz, Howard Love, PJC |